



FIERCE 15

Verdiva Bio Selected by Fierce Biotech as a “Fierce 15” Winner of 2025

LONDON AND SAN FRANCISCO – 22 September, 2025 – Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing next-generation, once-weekly oral therapies for obesity and cardiometabolic disorders, has been named by leading industry publication, Fierce Biotech, as one of 2025’s Fierce 15 biotechnology companies, designating it as a private biotechnology company *“turning heads—and turning the tide—in drug development and beyond”*.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 23rd annual Fierce 15 selection. Find the full report [here](#).

Khurem Farooq, CEO of Verdiva Bio commented:

“This recognition by Fierce Biotech as one of the most innovative private biotech’s is a testament to the dedication of our talented team and the potential of our flexible, modular portfolio. Our lead investigational programs, VRB-101, a once-weekly oral GLP-1 receptor agonist, and VRB-103, a once-weekly oral amylin analog, exemplify our commitment to developing patient-friendly, scalable therapies that address key challenges faced by people living with obesity and cardiometabolic disorders.”

Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare said:

“Over the past 23 years, our Fierce 15 special report has spotlighted the private biotechs pushing science into uncharted territory, whose approaches and discoveries represent genuine leaps forward. This year we’ve selected 15 pre-commercial biotechs that are advancing transformative science in an unrelenting industry landscape. These companies exemplify the innovation and determination driving the next generation of therapies that will hopefully benefit patients worldwide.”

-Ends-

Contact Information

Verdiva Bio

Charlotte Davison, Chief of Staff

info@verdivabio.com

Vigo Consulting (Media)

Melanie Toyne-Sewell

Rozi Morris

+44 20 7390 0230

VerdivaBio@VigoConsulting.com**About Verdiva Bio**

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

For more information, please visit www.verdivabio.com.

About Fierce Biotech

Fierce Biotech covers the biopharma waterfront, from drug development through the entire lifecycle—tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Our aim is to analyze the day's news, showing readers not only what they need to know, but why they need to know it. Beyond the daily, the Fierce Biotech team produces special reports that take stock of the industry's products and finances and shed new light on industry trends.

www.fiercebiotech.com